首页 > 最新文献

Drug Design, Development and Therapy最新文献

英文 中文
Aqueous Extract of Rhubarb Promotes Hepatotoxicity via Facilitating PKM2-Mediated Aerobic Glycolysis in a Rat Model of Diethylnitrosamine-Induced Liver Cancer. 在二乙基亚硝胺诱发肝癌的大鼠模型中,大黄水提取物通过促进 PKM2 介导的有氧糖酵解来增强肝毒性
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S476273
Anni Zhao, Xiaomei Liu, Xiping Chen, Sha Na, Hui Wang, Xuan Peng, Peizhong Kong, Lu Li

Objective: To identify the polar parts in Rhubarb that cause hepatotoxicity and explore the underlying mechanisms.

Methods: The rat model of liver cancer was established by gavage of diethylnitrosamine (DEN; 0.002 g/rat) for 14 weeks. Starting from the 11th week, Rhubarb granule (4 g/kg), aqueous, ethyl acetate and n-butanol extract of Rhubarb or Rhein equivalent to a dose of 4 g/kg Rhubarb granule were administered intragastrically for 4 consecutive weeks. Liver tissues from rats treated with DEN and Rhubarb granules were used for non-targeted metabolomics analysis. The correlation between pyruvate kinase isozyme type M2 (PKM2) expression level and the progress and prognosis of hepatocellular carcinoma (HCC) was evaluated through bioinformatics analysis based on TCGA database. Liver tissues and blood samples from rats treated with DEN and aqueous, ethyl acetate and n-butanol extract of Rhubarb were used for the screening of hepatotoxic polar parts of Rhubarb. The liver injuries were evaluated by the changes in pathology, liver function, and the expression levels of proliferating cell nuclear antigen (PCNA) and transforming growth factor beta1 (TGF-β1). The mechanism studies focus on PKM2 expression, and the metabolic reprogramming via detecting the activities of lactate dehydrogenase A (LDHA) and isocitrate dehydrogenase (ICDH). Furthermore, molecular docking analysis was performed to validate the target interaction between Rhein and PKM2, and the hepatotoxicity of Rhein was evaluated by testing liver function in the DEN-induced liver cancer model.

Results: The non-targeted metabolomics analysis revealed that Rhubarb promoted aerobic glycolysis in the rat model of DEN-induced liver cancer. And bioinformatics analysis revealed that high PKM2 expression was closely related to the progression and poor prognosis of HCC. In vivo studies indicated that the aqueous extract of Rhubarb, but not ethyl acetate and n-butanol extract, promoted the liver injuries induced by DEN. The mechanism study showed that the aqueous extract of Rhubarb increased the expression of PKM2 and promoted aerobic glycolysis. Moreover, Rhein had a strong binding affinity for PKM2 and aggravated liver injury in the DEN-induced liver cancer model.

Conclusion: Aqueous extract of Rhubarb promoted hepatotoxicity via facilitating PKM2-mediated aerobic glycolysis in the rat model of DEN-induced liver cancer.

目的确定大黄中导致肝毒性的极性成分,并探索其潜在机制:大鼠肝癌模型通过灌胃二乙基亚硝胺(DEN;0.002 克/只)建立,为期 14 周。从第 11 周开始,大黄颗粒(4 克/千克)、大黄水提取物、乙酸乙酯提取物和正丁醇提取物或大黄素(相当于 4 克/千克大黄颗粒的剂量)被连续灌胃 4 周。用 DEN 和大黄颗粒处理的大鼠肝组织用于非靶向代谢组学分析。通过基于TCGA数据库的生物信息学分析,评估了丙酮酸激酶同工酶M2型(PKM2)表达水平与肝细胞癌(HCC)的进展和预后之间的相关性。大黄水提取物、乙酸乙酯提取物和正丁醇提取物用于筛选大黄的肝毒性极性部位。肝损伤通过病理变化、肝功能、增殖细胞核抗原(PCNA)和转化生长因子β1(TGF-β1)的表达水平进行评估。机理研究的重点是 PKM2 的表达,以及通过检测乳酸脱氢酶 A(LDHA)和异柠檬酸脱氢酶(ICDH)的活性实现代谢重编程。此外,还进行了分子对接分析以验证Rhein与PKM2之间的靶向相互作用,并在DEN诱导的肝癌模型中通过检测肝功能评估了Rhein的肝毒性:结果:非靶向代谢组学分析表明,大黄能促进DEN诱导肝癌大鼠模型的有氧糖酵解。生物信息学分析表明,PKM2 的高表达与 HCC 的进展和预后不良密切相关。体内研究表明,大黄水提取物能促进DEN诱导的肝损伤,而乙酸乙酯和正丁醇提取物不能。机理研究表明,大黄水提取物能增加 PKM2 的表达,促进有氧糖酵解。此外,大黄苷与PKM2有很强的结合亲和力,能加重DEN诱导的肝癌模型的肝损伤:结论:大黄水提取物通过促进PKM2介导的有氧糖酵解,在大鼠DEN诱导的肝癌模型中促进肝毒性。
{"title":"Aqueous Extract of Rhubarb Promotes Hepatotoxicity via Facilitating PKM2-Mediated Aerobic Glycolysis in a Rat Model of Diethylnitrosamine-Induced Liver Cancer.","authors":"Anni Zhao, Xiaomei Liu, Xiping Chen, Sha Na, Hui Wang, Xuan Peng, Peizhong Kong, Lu Li","doi":"10.2147/DDDT.S476273","DOIUrl":"https://doi.org/10.2147/DDDT.S476273","url":null,"abstract":"<p><strong>Objective: </strong>To identify the polar parts in Rhubarb that cause hepatotoxicity and explore the underlying mechanisms.</p><p><strong>Methods: </strong>The rat model of liver cancer was established by gavage of diethylnitrosamine (DEN; 0.002 g/rat) for 14 weeks. Starting from the 11th week, Rhubarb granule (4 g/kg), aqueous, ethyl acetate and n-butanol extract of Rhubarb or Rhein equivalent to a dose of 4 g/kg Rhubarb granule were administered intragastrically for 4 consecutive weeks. Liver tissues from rats treated with DEN and Rhubarb granules were used for non-targeted metabolomics analysis. The correlation between pyruvate kinase isozyme type M2 (PKM2) expression level and the progress and prognosis of hepatocellular carcinoma (HCC) was evaluated through bioinformatics analysis based on TCGA database. Liver tissues and blood samples from rats treated with DEN and aqueous, ethyl acetate and n-butanol extract of Rhubarb were used for the screening of hepatotoxic polar parts of Rhubarb. The liver injuries were evaluated by the changes in pathology, liver function, and the expression levels of proliferating cell nuclear antigen (PCNA) and transforming growth factor beta1 (TGF-β1). The mechanism studies focus on PKM2 expression, and the metabolic reprogramming via detecting the activities of lactate dehydrogenase A (LDHA) and isocitrate dehydrogenase (ICDH). Furthermore, molecular docking analysis was performed to validate the target interaction between Rhein and PKM2, and the hepatotoxicity of Rhein was evaluated by testing liver function in the DEN-induced liver cancer model.</p><p><strong>Results: </strong>The non-targeted metabolomics analysis revealed that Rhubarb promoted aerobic glycolysis in the rat model of DEN-induced liver cancer. And bioinformatics analysis revealed that high PKM2 expression was closely related to the progression and poor prognosis of HCC. In vivo studies indicated that the aqueous extract of Rhubarb, but not ethyl acetate and n-butanol extract, promoted the liver injuries induced by DEN. The mechanism study showed that the aqueous extract of Rhubarb increased the expression of PKM2 and promoted aerobic glycolysis. Moreover, Rhein had a strong binding affinity for PKM2 and aggravated liver injury in the DEN-induced liver cancer model.</p><p><strong>Conclusion: </strong>Aqueous extract of Rhubarb promoted hepatotoxicity via facilitating PKM2-mediated aerobic glycolysis in the rat model of DEN-induced liver cancer.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4497-4510"},"PeriodicalIF":4.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Network Pharmacology and Experimental Verification: SanQi-DanShen Treats Coronary Heart Disease by Inhibiting the PI3K/AKT Signaling Pathway. 网络药理学与实验验证:三七丹参通过抑制 PI3K/AKT 信号通路治疗冠心病
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S480248
Min Zhao, Liuxiang Feng, Wenhua Li

Objective: To employee network pharmacology to predict the components and pathways of SanQi-DanShen (SQDS) in treating coronary heart disease, followed by in vitro experiments to validate the molecular mechanism of SQDS in treating coronary heart disease.

Methods: We sourced the active ingredients and targets of Panax notoginseng and Danshen from the Traditional Chinese Medicine Systems Pharmacology database. Coronary heart disease related genes were retrieved from the OMIM, Genecards, and Therapeutic Target databases. Using Cytoscape 3.7.2 software, we constructed a network diagram illustrating the components and targets of SQDS. The associated targets were then imported into the STRING database to build a protein-protein interaction network. The Metascape database and WeChat software were utilized for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Lastly, we performed molecular docking between the key components and related targets using AutoDock Vina. To validate the potential mechanism of SQDS in treating coronary heart disease, we established an acute coronary heart disease rat model via tail vein injection of pituitrin.

Results: Network pharmacology analysis revealed that 65 active ingredients and 167 targets of SQDS are implicated in the treatment of coronary heart disease. The key targets identified include AKT1, TNF, TP53, IL6, and VEGFA. Notably, the PI3K/AKT signaling pathway emerged as the primary pathway. Furthermore, animal experiments showed that, compared to the model group, SQDS significantly reduced levels of TNF-α, IL-6, Bax, and cardiac troponin I, while increasing Bcl-2 content. It also notably suppressed the expression of p-PI3K and p-AKT, thereby offering protection to myocardial tissue.

Conclusion: Through the integrated approach of network pharmacology and molecular docking, we have established that SQDS exerts a multi-component, multi-target, and multi-pathway synergistic therapeutic effect on coronary heart disease. Its mechanism may involve the inhibition of the PI3K/AKT signaling pathway and the reduction of inflammatory factor expression.

目的利用网络药理学预测三七丹参治疗冠心病的成分和途径,并通过体外实验验证三七丹参治疗冠心病的分子机制:方法:我们从中药系统药理学数据库中获取了三七和丹参的有效成分和靶点。冠心病相关基因来自 OMIM、Genecards 和 Therapeutic Target 数据库。我们使用 Cytoscape 3.7.2 软件构建了一个网络图,说明了 SQDS 的组成和靶标。然后将相关靶标导入 STRING 数据库,构建蛋白质-蛋白质相互作用网络。我们利用 Metascape 数据库和微信软件进行了基因本体和京都基因和基因组百科全书的富集分析。最后,我们使用 AutoDock Vina 在关键成分和相关靶标之间进行了分子对接。为了验证 SQDS 治疗冠心病的潜在机制,我们通过尾静脉注射垂体促肾上腺皮质激素建立了急性冠心病大鼠模型:网络药理学分析表明,SQDS 的 65 种活性成分和 167 个靶点与冠心病的治疗有关。发现的关键靶点包括 AKT1、TNF、TP53、IL6 和 VEGFA。值得注意的是,PI3K/AKT 信号通路成为主要通路。此外,动物实验表明,与模型组相比,SQDS 能显著降低 TNF-α、IL-6、Bax 和心肌肌钙蛋白 I 的水平,同时增加 Bcl-2 的含量。它还能明显抑制 p-PI3K 和 p-AKT 的表达,从而为心肌组织提供保护:通过网络药理学和分子对接的综合方法,我们确定了 SQDS 对冠心病具有多成分、多靶点、多途径的协同治疗作用。其机制可能包括抑制 PI3K/AKT 信号通路和减少炎症因子的表达。
{"title":"Network Pharmacology and Experimental Verification: SanQi-DanShen Treats Coronary Heart Disease by Inhibiting the PI3K/AKT Signaling Pathway.","authors":"Min Zhao, Liuxiang Feng, Wenhua Li","doi":"10.2147/DDDT.S480248","DOIUrl":"https://doi.org/10.2147/DDDT.S480248","url":null,"abstract":"<p><strong>Objective: </strong>To employee network pharmacology to predict the components and pathways of SanQi-DanShen (SQDS) in treating coronary heart disease, followed by in vitro experiments to validate the molecular mechanism of SQDS in treating coronary heart disease.</p><p><strong>Methods: </strong>We sourced the active ingredients and targets of Panax notoginseng and Danshen from the Traditional Chinese Medicine Systems Pharmacology database. Coronary heart disease related genes were retrieved from the OMIM, Genecards, and Therapeutic Target databases. Using Cytoscape 3.7.2 software, we constructed a network diagram illustrating the components and targets of SQDS. The associated targets were then imported into the STRING database to build a protein-protein interaction network. The Metascape database and WeChat software were utilized for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses. Lastly, we performed molecular docking between the key components and related targets using AutoDock Vina. To validate the potential mechanism of SQDS in treating coronary heart disease, we established an acute coronary heart disease rat model via tail vein injection of pituitrin.</p><p><strong>Results: </strong>Network pharmacology analysis revealed that 65 active ingredients and 167 targets of SQDS are implicated in the treatment of coronary heart disease. The key targets identified include AKT1, TNF, TP53, IL6, and VEGFA. Notably, the PI3K/AKT signaling pathway emerged as the primary pathway. Furthermore, animal experiments showed that, compared to the model group, SQDS significantly reduced levels of TNF-α, IL-6, Bax, and cardiac troponin I, while increasing Bcl-2 content. It also notably suppressed the expression of p-PI3K and p-AKT, thereby offering protection to myocardial tissue.</p><p><strong>Conclusion: </strong>Through the integrated approach of network pharmacology and molecular docking, we have established that SQDS exerts a multi-component, multi-target, and multi-pathway synergistic therapeutic effect on coronary heart disease. Its mechanism may involve the inhibition of the PI3K/AKT signaling pathway and the reduction of inflammatory factor expression.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4529-4550"},"PeriodicalIF":4.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of a Radio-Iodinated Alpha-Mangostin for Targeting Estrogen Receptor Alpha (ERα) in Breast Cancer: In Silico Design, Synthesis, and Biological Evaluation. 放射性碘化α-曼戈斯汀靶向乳腺癌雌激素受体α(ERα)的研究:In Silico Design, Synthesis, and Biological Evaluation.
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S479447
Muchtaridi Muchtaridi, Wiwit Nurhidayah, Taufik Muhammad Fakih, Kento Kannaka, Hiroyuki Suzuki, Toto Subroto, Tomoya Uehara

Introduction: Alpha-mangostin (AM), the most representative xanthone derivative isolated from the rind of the Purple Mangosteen (Garcinia mangostana Linn), has been reported pharmacologically to be associated with breast cancer in silico, in vitro, and in vivo. Although the pharmacological effects of AM are believed to involve the estrogen receptor alpha (ERα), there are no reports available in the literature describing the binding of AM to ERα.

Methods: In this study, iodine-125 (125I)-labeled AM ([125I]I-AM) was prepared, and its binding to ERα was investigated in vitro using MCF-7 cell lines. To investigate the applicability of radioiodine-labeled AM as a radiopharmaceutical for breast cancer, [125I]I-AM was injected into nude mice bearing MCF-7.

Results: The results obtained showed that the uptake of [125I]I-AM into MCF-7 cells was found to be inhibited by AM and tamoxifen, suggesting that its uptake is partially mediated by ERα. In addition, the biodistribution studies using MCF-7 bearing nude mice showed that [125I]I-AM accumulated in tumor tissues, although deiodination did occur, reducing the concentration of iodine-125 (125I) in the targeted cells.

Conclusion: These results suggested that AM would be a useful platform for the development of a new radiopharmaceutical targeting ERα. Further studies are, however, required to reduce deiodination of [125I]I-AM in vivo.

简介:α-山竹素(AM)是从紫山竹(Garcinia mangostana Linn)果皮中分离出来的最具代表性的氧杂蒽酮衍生物,据药理学报道,在硅学、体外和体内与乳腺癌有关。虽然 AM 的药理作用被认为涉及雌激素受体α(ERα),但文献中没有关于 AM 与 ERα 结合的报道:本研究制备了碘-125(125I)标记的AM([125I]I-AM),并利用MCF-7细胞系对其与ERα的结合进行了体外研究。为了研究放射性碘标记 AM 作为乳腺癌放射性药物的适用性,向携带 MCF-7 的裸鼠注射了[125I]I-AM:结果表明,MCF-7 细胞对[125I]I-AM 的摄取受到 AM 和他莫昔芬的抑制,表明其摄取部分由 ERα 介导。此外,利用携带 MCF-7 的裸鼠进行的生物分布研究表明,[125I]I-AM 在肿瘤组织中积累,尽管脱碘反应确实发生,降低了靶细胞中碘-125(125I)的浓度:这些结果表明,AM 将是开发靶向 ERα 的新型放射性药物的有用平台。不过,还需要进一步研究如何减少[125I]I-AM在体内的脱碘现象。
{"title":"Investigation of a Radio-Iodinated Alpha-Mangostin for Targeting Estrogen Receptor Alpha (ERα) in Breast Cancer: In Silico Design, Synthesis, and Biological Evaluation.","authors":"Muchtaridi Muchtaridi, Wiwit Nurhidayah, Taufik Muhammad Fakih, Kento Kannaka, Hiroyuki Suzuki, Toto Subroto, Tomoya Uehara","doi":"10.2147/DDDT.S479447","DOIUrl":"https://doi.org/10.2147/DDDT.S479447","url":null,"abstract":"<p><strong>Introduction: </strong>Alpha-mangostin (AM), the most representative xanthone derivative isolated from the rind of the Purple Mangosteen (Garcinia mangostana Linn), has been reported pharmacologically to be associated with breast cancer in silico, in vitro, and in vivo. Although the pharmacological effects of AM are believed to involve the estrogen receptor alpha (ERα), there are no reports available in the literature describing the binding of AM to ERα.</p><p><strong>Methods: </strong>In this study, iodine-125 (<sup>125</sup>I)-labeled AM ([<sup>125</sup>I]I-AM) was prepared, and its binding to ERα was investigated in vitro using MCF-7 cell lines. To investigate the applicability of radioiodine-labeled AM as a radiopharmaceutical for breast cancer, [<sup>125</sup>I]I-AM was injected into nude mice bearing MCF-7.</p><p><strong>Results: </strong>The results obtained showed that the uptake of [<sup>125</sup>I]I-AM into MCF-7 cells was found to be inhibited by AM and tamoxifen, suggesting that its uptake is partially mediated by ERα. In addition, the biodistribution studies using MCF-7 bearing nude mice showed that [<sup>125</sup>I]I-AM accumulated in tumor tissues, although deiodination did occur, reducing the concentration of iodine-125 (<sup>125</sup>I) in the targeted cells.</p><p><strong>Conclusion: </strong>These results suggested that AM would be a useful platform for the development of a new radiopharmaceutical targeting ERα. Further studies are, however, required to reduce deiodination of [<sup>125</sup>I]I-AM in vivo.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4511-4526"},"PeriodicalIF":4.7,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11471106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dexmedetomidine and Dexamethasone as Adjuvants to the Local Anesthetic Mixture in Rhomboid Intercostal and Sub-Serratus Block for Video-Assisted Thoracoscopic Surgery: A Randomized, Double-Blind, Controlled Trial. 右美托咪定和地塞米松作为视频辅助胸腔镜手术中横纹肌肋间和剑突下阻滞的局麻药混合物的辅助剂:随机、双盲、对照试验。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S476929
Quan-Fang Liu, Cui-Na Shi, Jian-Hua Tong, Kun-Peng Li, Jian-Jun Yang, Mu-Huo Ji, Qing-Ren Liu

Background: The utilization of adjuvants such as dexamethasone and dexmedetomidine in combination with local anesthetics has proven effective in extending analgesia duration. We aimed to investigate the potential efficacy of combining dexmedetomidine and dexamethasone in rhomboid intercostal and sub-serratus (RISS) block for prolonging postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery (VATS).

Methods: We did this randomized, double-blind, controlled trial in two tertiary-care hospitals. A total of eighty-eight patients undergoing VATS under general anesthesia were enrolled in this study. They were randomly assigned into four groups: ropivacaine (R) group, ropivacaine + dexmedetomidine (RM) group, ropivacaine + dexamethasone (RS) group, or ropivacaine + dexmedetomidine + dexamethasone (RSM) group. The primary outcome measure was the duration of analgesia. Secondary outcomes included Numeric Rating Scale (NRS) scores, cumulative oxycodone consumption, and adverse effects.

Results: The RSM group exhibited a significantly prolonged duration of analgesia at 1073.5 min (932.0-1283.3) compared to the R group with a duration of 154.5 min (80.5-199.3) and the RS group with a duration of 282.0 min (195.3-350.0, P < 0 0.001). The cumulative oxycodone consumption during the 0-12 hours and 0-24-hours period was significantly reduced in the RSM group compared to the R group (P < 0.05). There was also a lower incidence of nausea at 48 hours postoperatively in the RSM group compared to the RM group. However, there were no significant differences between the four groups regarding NRS pain scores.

Conclusion: The combination of ropivacaine, dexmedetomidine, and dexamethasone in RISS block significantly prolongs the duration of postoperative analgesia following VATS.

背景:事实证明,地塞米松和右美托咪定等辅助剂与局麻药联合使用可有效延长镇痛时间。我们旨在研究将右美托咪定和地塞米松联合应用于斜方肌肋间和锯齿下(RISS)阻滞以延长视频辅助胸腔镜手术(VATS)患者术后镇痛的潜在疗效:我们在两家三级医院进行了这项随机、双盲、对照试验。共有 88 名在全身麻醉下接受 VATS 手术的患者参与了这项研究。他们被随机分为四组:罗哌卡因(R)组、罗哌卡因+右美托咪定(RM)组、罗哌卡因+地塞米松(RS)组或罗哌卡因+右美托咪定+地塞米松(RSM)组。主要结果是镇痛持续时间。次要结果包括数值评定量表(NRS)评分、累计羟考酮用量和不良反应:结果:RSM 组的镇痛持续时间为 1073.5 分钟(932.0-1283.3),明显长于 R 组的 154.5 分钟(80.5-199.3)和 RS 组的 282.0 分钟(195.3-350.0,P < 0.001)。与 R 组相比,RSM 组在 0-12 小时和 0-24 小时期间的累计羟考酮用量明显减少(P < 0.05)。此外,RSM 组术后 48 小时的恶心发生率也低于 RM 组。然而,四组患者的 NRS 疼痛评分无明显差异:结论:在 RISS 阻滞中联合使用罗哌卡因、右美托咪定和地塞米松可显著延长 VATS 术后镇痛的持续时间。
{"title":"Dexmedetomidine and Dexamethasone as Adjuvants to the Local Anesthetic Mixture in Rhomboid Intercostal and Sub-Serratus Block for Video-Assisted Thoracoscopic Surgery: A Randomized, Double-Blind, Controlled Trial.","authors":"Quan-Fang Liu, Cui-Na Shi, Jian-Hua Tong, Kun-Peng Li, Jian-Jun Yang, Mu-Huo Ji, Qing-Ren Liu","doi":"10.2147/DDDT.S476929","DOIUrl":"https://doi.org/10.2147/DDDT.S476929","url":null,"abstract":"<p><strong>Background: </strong>The utilization of adjuvants such as dexamethasone and dexmedetomidine in combination with local anesthetics has proven effective in extending analgesia duration. We aimed to investigate the potential efficacy of combining dexmedetomidine and dexamethasone in rhomboid intercostal and sub-serratus (RISS) block for prolonging postoperative analgesia in patients undergoing video-assisted thoracoscopic surgery (VATS).</p><p><strong>Methods: </strong>We did this randomized, double-blind, controlled trial in two tertiary-care hospitals. A total of eighty-eight patients undergoing VATS under general anesthesia were enrolled in this study. They were randomly assigned into four groups: ropivacaine (R) group, ropivacaine + dexmedetomidine (RM) group, ropivacaine + dexamethasone (RS) group, or ropivacaine + dexmedetomidine + dexamethasone (RSM) group. The primary outcome measure was the duration of analgesia. Secondary outcomes included Numeric Rating Scale (NRS) scores, cumulative oxycodone consumption, and adverse effects.</p><p><strong>Results: </strong>The RSM group exhibited a significantly prolonged duration of analgesia at 1073.5 min (932.0-1283.3) compared to the R group with a duration of 154.5 min (80.5-199.3) and the <i>RS</i> group with a duration of 282.0 min (195.3-350.0, <i>P</i> < 0 0.001). The cumulative oxycodone consumption during the 0-12 hours and 0-24-hours period was significantly reduced in the RSM group compared to the R group (<i>P</i> < 0.05). There was also a lower incidence of nausea at 48 hours postoperatively in the RSM group compared to the RM group. However, there were no significant differences between the four groups regarding NRS pain scores.</p><p><strong>Conclusion: </strong>The combination of ropivacaine, dexmedetomidine, and dexamethasone in RISS block significantly prolongs the duration of postoperative analgesia following VATS.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4485-4496"},"PeriodicalIF":4.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11468391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Mesenchymal Stem Cell-Based NK4 Gene Therapy in Nude Mice Bearing Gastric Cancer Xenografts [Corrigendum]. 勘误:基于间充质干细胞的 NK4 基因疗法在携带胃癌异种移植物的裸鼠中的应用 [更正]。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S493671

[This corrects the article DOI: 10.2147/DDDT.S71466.].

[此处更正了文章 DOI:10.2147/DDDT.S71466]。
{"title":"Erratum: Mesenchymal Stem Cell-Based <i>NK4</i> Gene Therapy in Nude Mice Bearing Gastric Cancer Xenografts [Corrigendum].","authors":"","doi":"10.2147/DDDT.S493671","DOIUrl":"https://doi.org/10.2147/DDDT.S493671","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.2147/DDDT.S71466.].</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4481-4483"},"PeriodicalIF":4.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sivelestat Sodium Alleviates Ischemia-Reperfusion-Induced Acute Kidney Injury via Suppressing TLR4/Myd88/NF-κB Signaling Pathway in Mice. 西维司他钠通过抑制TLR4/Myd88/NF-κB信号通路缓解小鼠缺血再灌注诱导的急性肾损伤
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S480148
Jie Wang, Yuanbo Wu, Meng Mao, Hailong Bing, Liwei Sun, Wei Xu, Wangli Tian, Zhengyuan Xia, Xiaogao Jin, Qinjun Chu

Purpose: We aim to detect the effects of sivelestat on renal ischemia-reperfusion associated with AKI and also explore the underlying mechanism.

Materials and methods: Mice, aged between 8 and 12 weeks, were randomly allocated among four distinct groups, respectively normal saline sham group(C), normal saline surgery group(I), sivelestat (50 mg/kg) sham group(S), sivelestat (50 mg/kg) surgery group(SI) (n=6, each group). In the surgical groups, the renal pedicles of mice were clamped with non-traumatic micro-aneurysm clamps, resulting in ischemia of the kidneys for 45 minutes. This was followed by a period of reperfusion lasting 24 hours. Sham group mice underwent the identical surgery produced without clamping renal pedicles. Mice blood was obtained from eyeballs, and Serum creatinine and blood urea nitrogen levels were measured. After a 24-hour period of reperfusion, the mice were euthanized, and their kidneys were gathered for various analyses, including Western Blot (WB) analysis, RT-PCR, immunofluorescence (IF), hematoxylin and eosin (H&E) staining, and Tunel assay.

Results: Pretreatments with sivelestat decreased renal Neutrophil elastase (NE), serum creatinine, and blood urea nitrogen levels after renal ischemia-reperfusion. Sivelestat also reduced histological damage and cell apoptosis in kidneys following ischemia-reperfusion injury (IRI). In addition, the sivelestat administration diminished the levels of mRNA expression of interleukin 6 (IL-6), Macrophage inflammatory protein-2 (MIP-2), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF)-α in the kidneys during IRI. The kidney tissues of the SI group had significantly mitigated TLR4, Myd88, and NF-κB p-p65 protein expression levels compared to the I group (all P<0.05).

Conclusion: We demonstrated a previously unidentified mechanism that sivelestat effectively attenuates AKI-induced renal dysfunction, possibly through suppressing the TLR4/Myd88/ NF-κB pathway.

目的:检测西维司他对AKI相关肾缺血再灌注的影响,并探讨其潜在机制:将8-12周龄的小鼠随机分为四组,分别为正常生理盐水假组(C)、正常生理盐水手术组(I)、西维司他(50 mg/kg)假组(S)、西维司他(50 mg/kg)手术组(SI)(每组n=6)。在手术组中,用非创伤性微型动脉瘤夹夹住小鼠的肾动脉,导致肾脏缺血 45 分钟。随后进行持续 24 小时的再灌注。假阴性组小鼠接受了相同的手术,但没有夹住肾蒂。小鼠眼球取血,测量血清肌酐和血尿素氮水平。再灌注 24 小时后,小鼠安乐死,收集肾脏进行各种分析,包括 Western Blot(WB)分析、RT-PCR、免疫荧光(IF)、苏木精和伊红(H&E)染色以及 Tunel 检测:结果:西维司他可降低肾缺血再灌注后的肾中性粒细胞弹性蛋白酶(NE)、血清肌酐和血尿素氮水平。西维司他还能减少缺血再灌注损伤(IRI)后肾脏的组织损伤和细胞凋亡。此外,西维司他还能降低IRI期间肾脏中白细胞介素6(IL-6)、巨噬细胞炎症蛋白-2(MIP-2)、单核细胞趋化蛋白-1(MCP-1)和肿瘤坏死因子(TNF)-α的mRNA表达水平。与I组相比,SI组肾脏组织中的TLR4、Myd88和NF-κB p-p65蛋白表达水平明显降低(均为PC):我们证明了西维司他可能通过抑制TLR4/Myd88/ NF-κB通路有效减轻AKI诱导的肾功能障碍的一种之前尚未发现的机制。
{"title":"Sivelestat Sodium Alleviates Ischemia-Reperfusion-Induced Acute Kidney Injury via Suppressing TLR4/Myd88/NF-κB Signaling Pathway in Mice.","authors":"Jie Wang, Yuanbo Wu, Meng Mao, Hailong Bing, Liwei Sun, Wei Xu, Wangli Tian, Zhengyuan Xia, Xiaogao Jin, Qinjun Chu","doi":"10.2147/DDDT.S480148","DOIUrl":"https://doi.org/10.2147/DDDT.S480148","url":null,"abstract":"<p><strong>Purpose: </strong>We aim to detect the effects of sivelestat on renal ischemia-reperfusion associated with AKI and also explore the underlying mechanism.</p><p><strong>Materials and methods: </strong>Mice, aged between 8 and 12 weeks, were randomly allocated among four distinct groups, respectively normal saline sham group(C), normal saline surgery group(I), sivelestat (50 mg/kg) sham group(S), sivelestat (50 mg/kg) surgery group(SI) (n=6, each group). In the surgical groups, the renal pedicles of mice were clamped with non-traumatic micro-aneurysm clamps, resulting in ischemia of the kidneys for 45 minutes. This was followed by a period of reperfusion lasting 24 hours. Sham group mice underwent the identical surgery produced without clamping renal pedicles. Mice blood was obtained from eyeballs, and Serum creatinine and blood urea nitrogen levels were measured. After a 24-hour period of reperfusion, the mice were euthanized, and their kidneys were gathered for various analyses, including Western Blot (WB) analysis, RT-PCR, immunofluorescence (IF), hematoxylin and eosin (H&E) staining, and Tunel assay.</p><p><strong>Results: </strong>Pretreatments with sivelestat decreased renal Neutrophil elastase (NE), serum creatinine, and blood urea nitrogen levels after renal ischemia-reperfusion. Sivelestat also reduced histological damage and cell apoptosis in kidneys following ischemia-reperfusion injury (IRI). In addition, the sivelestat administration diminished the levels of mRNA expression of interleukin 6 (IL-6), Macrophage inflammatory protein-2 (MIP-2), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF)-α in the kidneys during IRI. The kidney tissues of the SI group had significantly mitigated TLR4, Myd88, and NF-κB p-p65 protein expression levels compared to the I group (all P<0.05).</p><p><strong>Conclusion: </strong>We demonstrated a previously unidentified mechanism that sivelestat effectively attenuates AKI-induced renal dysfunction, possibly through suppressing the TLR4/Myd88/ NF-κB pathway.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4449-4458"},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the ED50 of Ciprofol Combined With or Without Fentanyl for Laryngeal Mask Airway Insertion in Children: A Prospective, Randomized, Open-Label, Dose-Response Trial. 儿童喉罩气道置入时异丙酚联合或不联合芬太尼的 ED50 比较:一项前瞻性、随机、开放标签、剂量反应试验。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S466603
Sicong Wang, Yan Li, Fang Chen, Hua-Cheng Liu, Lezhou Pan, Wangning Shangguan

Purpose: This study aimed to estimate the effect of different doses of fentanyl on the median effective dose (ED50) of ciprofol for attenuating the airway and motor response to laryngeal mask airway (LMA) insertion response in healthy children.

Patients and methods: 90 healthy preschool patients undergoing inguinal hernia repair surgery were randomly assigned to one of three groups: C0 (ciprofol+saline), C1 (ciprofol + fentanyl 1µg/kg), C2 (ciprofol + fentanyl 2µg/kg). Anesthesia was induced with either prepared fentanyl or saline, followed by ciprofol. The dose of ciprofol for each patient was determined using the up-and-down sequential study design. The primary outcome was the ED50 of ciprofol required for smooth LMA insertion in the three groups. Additionally, the time to loss of consciousness and any perioperative adverse events were recorded.

Results: Compared with the C0 group, the ED50 (95% confidence interval) of ciprofol in the C1 and C2 groups were significantly lower (1.81 [1.73-1.90]mg/kg versus 0.67 [0.64-0.71]mg/kg and 0.48 [0.42-0.54] mg/kg, respectively; P<0.05). Additionally, the ED50 of ciprofol in the C2 group was lower than that in the C1 group (0.42 [0.42-0.54] mg/kg vs 0.67 [0.64-0.71]mg/kg; P<0.05). Furthermore, the time to loss of consciousness in the C1 and C2 groups decreased by 60% and 53%, respectively, compared to the C0 group. There were no significant differences in the incidence of drug-related hypotension after anesthesia induction among the three groups. No adverse events of hypoxia, bradycardia, or injection pain were observed in any groups.

Conclusion: In healthy, non-obese Chinese children undergoing elective inguinal hernia repair surgery, fentanyl 1 µg/kg and 2 µg/kg before ciprofol injection significantly reduced the ED50 of ciprofol for attenuating LMA response, with minimal occurrence of severe side effects.

目的:本研究旨在估算不同剂量的芬太尼对环丙酚中位有效剂量(ED50)的影响,环丙酚可减轻健康儿童对喉罩气道(LMA)插入反应的气道和运动反应。患者和方法:90 名接受腹股沟疝修补手术的健康学龄前患者被随机分配到三组中的一组:C0(环丙酚+生理盐水)、C1(环丙酚+芬太尼 1µg/kg)、C2(环丙酚+芬太尼 2µg/kg)。先用准备好的芬太尼或生理盐水进行麻醉,然后再用环丙酚。采用上下顺序研究设计确定了每位患者的环丙酚剂量。主要结果是三组患者顺利插入 LMA 所需的环丙酚 ED50。此外,还记录了意识丧失时间和任何围手术期不良事件:结果:与 C0 组相比,C1 组和 C2 组的环丙酚 ED50(95% 置信区间)显著较低(分别为 1.81 [1.73-1.90]mg/kg 对 0.67 [0.64-0.71]mg/kg 和 0.48 [0.42-0.54] mg/kg;PC 结论:在健康非肥胖的中国儿童中,环丙酚的 ED50(95% 置信区间)显著较低:在接受腹股沟疝修补术的健康非肥胖中国儿童中,注射环丙酚前使用芬太尼1微克/千克和2微克/千克可显著降低环丙酚减弱LMA反应的ED50,且严重副作用极小。
{"title":"Comparison of the ED50 of Ciprofol Combined With or Without Fentanyl for Laryngeal Mask Airway Insertion in Children: A Prospective, Randomized, Open-Label, Dose-Response Trial.","authors":"Sicong Wang, Yan Li, Fang Chen, Hua-Cheng Liu, Lezhou Pan, Wangning Shangguan","doi":"10.2147/DDDT.S466603","DOIUrl":"10.2147/DDDT.S466603","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to estimate the effect of different doses of fentanyl on the median effective dose (ED50) of ciprofol for attenuating the airway and motor response to laryngeal mask airway (LMA) insertion response in healthy children.</p><p><strong>Patients and methods: </strong>90 healthy preschool patients undergoing inguinal hernia repair surgery were randomly assigned to one of three groups: C0 (ciprofol+saline), C1 (ciprofol + fentanyl 1µg/kg), C2 (ciprofol + fentanyl 2µg/kg). Anesthesia was induced with either prepared fentanyl or saline, followed by ciprofol. The dose of ciprofol for each patient was determined using the up-and-down sequential study design. The primary outcome was the ED50 of ciprofol required for smooth LMA insertion in the three groups. Additionally, the time to loss of consciousness and any perioperative adverse events were recorded.</p><p><strong>Results: </strong>Compared with the C0 group, the ED50 (95% confidence interval) of ciprofol in the C1 and C2 groups were significantly lower (1.81 [1.73-1.90]mg/kg versus 0.67 [0.64-0.71]mg/kg and 0.48 [0.42-0.54] mg/kg, respectively; P<0.05). Additionally, the ED50 of ciprofol in the C2 group was lower than that in the C1 group (0.42 [0.42-0.54] mg/kg vs 0.67 [0.64-0.71]mg/kg; P<0.05). Furthermore, the time to loss of consciousness in the C1 and C2 groups decreased by 60% and 53%, respectively, compared to the C0 group. There were no significant differences in the incidence of drug-related hypotension after anesthesia induction among the three groups. No adverse events of hypoxia, bradycardia, or injection pain were observed in any groups.</p><p><strong>Conclusion: </strong>In healthy, non-obese Chinese children undergoing elective inguinal hernia repair surgery, fentanyl 1 µg/kg and 2 µg/kg before ciprofol injection significantly reduced the ED50 of ciprofol for attenuating LMA response, with minimal occurrence of severe side effects.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4471-4480"},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. 接受持续肾脏替代疗法的重症患者服用替加环素的群体药代动力学。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-05 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S473080
Shuping Song, Jieqiong Liu, Wei Su, Haitao Yu, Binbin Feng, Yinshan Wu, Feng Guo, Zhenwei Yu

Background: Tigecycline is considered one of the last resorts for treating infections caused by multidrug-resistant bacteria. Continuous renal replacement therapy (CRRT) is widely used in critically ill patients, especially those with acute kidney injury or severe infections. However, pharmacokinetic data for tigecycline in patients receiving CRRT are limited.

Methods: This was a single-center prospective clinical study with intensive sampling that included critically ill patients who received tigecycline and CRRT. A population pharmacokinetic (PPK) model was developed and evaluated by goodness-of-fit plots, bootstrap analysis, visual predictive checks, and numerical predictive checks. Pharmacokinetic/pharmacodynamic target attainment and cumulative fraction of response analyses were performed to explore the potential need for dose adjustments of tigecycline in CRRT.

Results: In total, 21 patients with 167 concentrations were included. A two-compartment model adequately described the tigecycline concentration-time points, but no covariates were found to adequately explain the viability in the pharmacokinetic parameters of tigecycline. The typical values of CL, Q, V1 and V2 were 4.42 L/h, 34.8 L/h, 30.9 L and 98.7 L, respectively. For most infections, the standard regimen of 50 mg/12 h was deemed appropriate, expect for skin and soft skin tissue infections and community-acquired pneumonia caused by Acinetobacter baumannii and Klebsiella pneumoniae, which required a dosage regimen of 100 mg/12 h or higher.

Conclusion: A tigecycline PPK model describing critically ill patients undergoing CRRT was successfully developed. The optimized dosage regimens for various infections are recommended.

背景:替加环素被认为是治疗耐多药细菌感染的最后手段之一。连续性肾脏替代疗法(CRRT)广泛用于重症患者,尤其是急性肾损伤或严重感染患者。然而,接受 CRRT 治疗的患者服用替加环素的药代动力学数据十分有限:方法:这是一项单中心前瞻性临床研究,采用密集采样法,纳入了接受替加环素和 CRRT 治疗的重症患者。研究建立了群体药代动力学(PPK)模型,并通过拟合优度图、自引导分析、视觉预测检查和数值预测检查进行了评估。进行了药代动力学/药效学目标达标分析和累积反应分数分析,以探讨在 CRRT 中调整替加环素剂量的潜在需求:结果:共纳入21名患者,167个浓度。两室模型充分描述了替加环素的浓度-时间点,但没有发现任何协变量能充分解释替加环素药代动力学参数的可行性。CL、Q、V1 和 V2 的典型值分别为 4.42 升/小时、34.8 升/小时、30.9 升和 98.7 升。对于大多数感染,50 毫克/12 小时的标准方案被认为是合适的,但对于由鲍曼不动杆菌和肺炎克雷伯菌引起的皮肤和皮肤软组织感染以及社区获得性肺炎,则需要 100 毫克/12 小时或更高的剂量方案:结论:我们成功地建立了一个替加环素PPK模型,用于描述接受CRRT治疗的重症患者。结论:成功建立了一个描述接受 CRRT 的重症患者的替加环素 PPK 模型,并推荐了针对各种感染的优化剂量方案。
{"title":"Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.","authors":"Shuping Song, Jieqiong Liu, Wei Su, Haitao Yu, Binbin Feng, Yinshan Wu, Feng Guo, Zhenwei Yu","doi":"10.2147/DDDT.S473080","DOIUrl":"10.2147/DDDT.S473080","url":null,"abstract":"<p><strong>Background: </strong>Tigecycline is considered one of the last resorts for treating infections caused by multidrug-resistant bacteria. Continuous renal replacement therapy (CRRT) is widely used in critically ill patients, especially those with acute kidney injury or severe infections. However, pharmacokinetic data for tigecycline in patients receiving CRRT are limited.</p><p><strong>Methods: </strong>This was a single-center prospective clinical study with intensive sampling that included critically ill patients who received tigecycline and CRRT. A population pharmacokinetic (PPK) model was developed and evaluated by goodness-of-fit plots, bootstrap analysis, visual predictive checks, and numerical predictive checks. Pharmacokinetic/pharmacodynamic target attainment and cumulative fraction of response analyses were performed to explore the potential need for dose adjustments of tigecycline in CRRT.</p><p><strong>Results: </strong>In total, 21 patients with 167 concentrations were included. A two-compartment model adequately described the tigecycline concentration-time points, but no covariates were found to adequately explain the viability in the pharmacokinetic parameters of tigecycline. The typical values of CL, Q, V1 and V2 were 4.42 L/h, 34.8 L/h, 30.9 L and 98.7 L, respectively. For most infections, the standard regimen of 50 mg/12 h was deemed appropriate, expect for skin and soft skin tissue infections and community-acquired pneumonia caused by <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>, which required a dosage regimen of 100 mg/12 h or higher.</p><p><strong>Conclusion: </strong>A tigecycline PPK model describing critically ill patients undergoing CRRT was successfully developed. The optimized dosage regimens for various infections are recommended.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4459-4469"},"PeriodicalIF":4.7,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review on Cassia alata Bioactive Compounds: In silico, in vitro, and in vivo Studies. 决明子生物活性化合物综述:硅学、体外和体内研究。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-04 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S477679
Michelle Natasha Colin, Nur Shelly Ester Claudiana, Annisa Utami Kaffah, Aliya Nur Hasanah, Sandra Megantara

Cassia alata Linn is a popular herbal remedy in many countries, and its activities have been studied through many studies, starting from in silico, in vitro, and in vivo. This narrative review will focus more on secondary metabolites that are responsible for certain pharmacological activities that have undergone in vivo, in vitro, and in silico testing to determine the underlying mechanism. Twenty pharmacological activities have been identified, with the flavonoid group (emodin, kaempferol, quercetin) as the most prevalent secondary metabolite found in Cassia alata. There have been numerous studies looking at the role of flavonoids about specific diseases, and flavonoid testing is quite thorough because it covers three different study types. However, there has not been significant progress accomplished in terms of the evaluation of the dosage form so that test results for promising activities like antidiabetic, antifungal, and antiviral can be carried out into further research. Additionally, several disorders lack comprehensive investigation, particularly in silico studies, therefore further study is required to fill any gaps in the knowledge.

决明子是一种在许多国家都很流行的草药,人们对它的活性进行了许多研究,包括硅学、体外和体内研究。本综述将更多地关注那些具有某些药理活性的次生代谢物,这些次生代谢物经过了体内、体外和硅学测试,以确定其基本机制。目前已确定了 20 种药理活性,其中黄酮类(大黄素、山柰醇、槲皮素)是决明中最常见的次生代谢物。关于类黄酮在特定疾病中的作用的研究不胜枚举,类黄酮的检测也相当全面,因为它涵盖了三种不同的研究类型。然而,在剂型评估方面还没有取得重大进展,因此无法对抗糖、抗真菌和抗病毒等有希望的活性进行进一步研究。此外,有几种疾病缺乏全面的调查,特别是缺乏硅学研究,因此需要进一步研究以填补知识空白。
{"title":"Review on <i>Cassia alata</i> Bioactive Compounds: In silico, in vitro, and in vivo Studies.","authors":"Michelle Natasha Colin, Nur Shelly Ester Claudiana, Annisa Utami Kaffah, Aliya Nur Hasanah, Sandra Megantara","doi":"10.2147/DDDT.S477679","DOIUrl":"https://doi.org/10.2147/DDDT.S477679","url":null,"abstract":"<p><p><i>Cassia alata</i> Linn is a popular herbal remedy in many countries, and its activities have been studied through many studies, starting from in silico, in vitro, and in vivo. This narrative review will focus more on secondary metabolites that are responsible for certain pharmacological activities that have undergone in vivo, in vitro, and in silico testing to determine the underlying mechanism. Twenty pharmacological activities have been identified, with the flavonoid group (emodin, kaempferol, quercetin) as the most prevalent secondary metabolite found in <i>Cassia alata</i>. There have been numerous studies looking at the role of flavonoids about specific diseases, and flavonoid testing is quite thorough because it covers three different study types. However, there has not been significant progress accomplished in terms of the evaluation of the dosage form so that test results for promising activities like antidiabetic, antifungal, and antiviral can be carried out into further research. Additionally, several disorders lack comprehensive investigation, particularly in silico studies, therefore further study is required to fill any gaps in the knowledge.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4427-4447"},"PeriodicalIF":4.7,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comprehensive Review of Coptidis Rhizoma and Magnoliae Officinalis Cortex Drug Pair and Their Chemical Composition, Pharmacological Effects and Pharmacokinetics Analysis. 黄连和厚朴药对及其化学成分、药理作用和药代动力学分析综述。
IF 4.7 2区 医学 Q1 CHEMISTRY, MEDICINAL Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI: 10.2147/DDDT.S477381
Qian Xie, Jiarou Chen, Hongyan Yang, Jianlong Liang, Rong Ma, Jialiang Guo, Xuxin Zeng

Herbal pairs are unique combinations of two relatively fixed herbs that are used in clinical practice. This is the most fundamental and straightforward form of multiple herbal treatment that aims to attain specific efficacy through unique methods. Coptidis Rhizoma ("Huanglian" in Chinese) and Magnoliae Officinalis Cortex ("Houpo" in Chinese) which are commonly used in combination and could also be used as important components of other prescriptions to treat damp-heat dysentery, splenic and stomach disorders, and qi stagnation in clinical practice. However, there is currently no summary on the compatibility of Huanglian and Houpo about traditional use, phytochemistry, and pharmacological activity. It was found the combination or separate extraction of the two drugs may affect the main active components, and new components may be produced after the combined extraction. At the same time, Huanglian and Houpo herb pair exhibited antiviral, anti-inflammatory, antibacterial and other pharmacological effects. At present, research mainly focuses on the indicator components of Huanglian and Houpo, such as berberine, magnolol, and magnolol. The models used for pharmacological validation are limited, mainly including ulcerative colitis, pneumonia, bacterial infections, etc. In order to verify the pharmacological activity of the combination of Huanglian and Houpo, it is necessary to try more in vitro and in vivo models. It's still need to study the compatibility mechanism of the Huanglian and Houpo drug pair, including but not limited to the interactions between different components and the impact of compatibility on efficacy, bioequivalence studies, and the impact of different dosage forms on pharmacokinetics in the future. It's believed that the systematic review provided comprehensive information for the study of Huanglian-Houpo drug pair, which will help highlight the importance of the Huanglian-Houpo herb pair and provide some clues for future research on this herb pair.

草药配对是两种相对固定的草药在临床上的独特组合。这是最基本、最直接的复方中药治疗形式,旨在通过独特的方法达到特定的疗效。临床上常用的黄连与厚朴配伍,也可作为治疗湿热痢疾、脾胃病、气滞证等其他方剂的重要组成成分。然而,目前还没有关于黄连和厚朴在传统用途、植物化学和药理活性方面相容性的总结。研究发现,两种药物的合并提取或单独提取可能会影响主要活性成分,合并提取后可能会产生新的成分。同时,黄连和厚朴这对药材具有抗病毒、抗炎、抗菌等药理作用。目前,研究主要集中在黄连和厚朴的指标成分,如小檗碱、木兰醇、木兰醇等。用于药理验证的模型有限,主要包括溃疡性结肠炎、肺炎、细菌感染等。为了验证黄连和厚朴复方制剂的药理活性,有必要尝试更多的体外和体内模型。未来还需要研究黄连与厚朴药物配伍的相容性机制,包括但不限于不同成分之间的相互作用、相容性对药效的影响、生物等效性研究、不同剂型对药代动力学的影响等。相信该系统综述为黄连厚朴药对的研究提供了全面的信息,有助于突出黄连厚朴药对的重要性,并为今后该药对的研究提供一些线索。
{"title":"A Comprehensive Review of Coptidis Rhizoma and Magnoliae Officinalis Cortex Drug Pair and Their Chemical Composition, Pharmacological Effects and Pharmacokinetics Analysis.","authors":"Qian Xie, Jiarou Chen, Hongyan Yang, Jianlong Liang, Rong Ma, Jialiang Guo, Xuxin Zeng","doi":"10.2147/DDDT.S477381","DOIUrl":"10.2147/DDDT.S477381","url":null,"abstract":"<p><p>Herbal pairs are unique combinations of two relatively fixed herbs that are used in clinical practice. This is the most fundamental and straightforward form of multiple herbal treatment that aims to attain specific efficacy through unique methods. Coptidis Rhizoma (\"Huanglian\" in Chinese) and Magnoliae Officinalis Cortex (\"Houpo\" in Chinese) which are commonly used in combination and could also be used as important components of other prescriptions to treat damp-heat dysentery, splenic and stomach disorders, and qi stagnation in clinical practice. However, there is currently no summary on the compatibility of Huanglian and Houpo about traditional use, phytochemistry, and pharmacological activity. It was found the combination or separate extraction of the two drugs may affect the main active components, and new components may be produced after the combined extraction. At the same time, Huanglian and Houpo herb pair exhibited antiviral, anti-inflammatory, antibacterial and other pharmacological effects. At present, research mainly focuses on the indicator components of Huanglian and Houpo, such as berberine, magnolol, and magnolol. The models used for pharmacological validation are limited, mainly including ulcerative colitis, pneumonia, bacterial infections, etc. In order to verify the pharmacological activity of the combination of Huanglian and Houpo, it is necessary to try more in vitro and in vivo models. It's still need to study the compatibility mechanism of the Huanglian and Houpo drug pair, including but not limited to the interactions between different components and the impact of compatibility on efficacy, bioequivalence studies, and the impact of different dosage forms on pharmacokinetics in the future. It's believed that the systematic review provided comprehensive information for the study of Huanglian-Houpo drug pair, which will help highlight the importance of the Huanglian-Houpo herb pair and provide some clues for future research on this herb pair.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"18 ","pages":"4413-4426"},"PeriodicalIF":4.7,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11456271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142380268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug Design, Development and Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1